PDCD1 and melanoma: Although still under continuous evaluation, both the expression of PD-L1 and a high mutational load have been associated with response to immune CPIs in clinical trials evaluating the efficacy of anti-PD-1-based therapies in melanoma, lung cancer, and TNBC [41–45].